Drug Safety Executive Council – De-Risking Drug Candidates in Early Clinical Development.

The session was conducted by the Drug Safety Executive Council and was entitled "De-Risking Drug Candidates in Early Clinical Development". The session focused on new and important approaches for improving cardiac safety characterization in early stage clinical development by collecting and analyzing continuous ECG data.

Panelists for the session included:

• Adel Nada, MD, MS, Medical Director, Clinical Pharmacology and Pharmacometrics, Global Pharmaceutical R & D, Abbott Laboratories
• Michael Wess, Medical Director, Pharmacovigilance and Global Safety Officer, Genzyme Corporation
• Sasha Latypova, Executive Vice President, iCardiac Technologies, Inc.
• Royce Morrison, Director, Clinical Research Strategy, Charles River Clinical Services